Bevacizumab treatment of macular edema in CRVO and BRVO: long-term follow-up (BERVOLT study: bevacizumab for RVO long-term follow-up)
- 195 Downloads
All authors have completed and submitted the ICMJE form for disclosure of potential conflicts of interest, and have no financial disclosures to report. Both authors (D.C. and M.C.) were involved in the design and conduct of the study, the collection, management, analysis and interpretation of the data, and the preparation, review and approval of the manuscript.
Compliance with ethical standards
The authors have full control of the primary data and have agreed to allow Graefe’s Archive for Clinical and Experimental Ophthalmology to review their data upon request.
Conflict of interest
All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.
- 7.Heier JS, Clark WL, Boyer DS, Brown DM, Vitti R, Berliner AJ, Kazmi H, Ma Y, Stemper B, Zeitz O, Sandbrink R, Haller JA (2014) Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion. Two-year results from the COPERNICUS study. Ophthalmology 121:1414–1420CrossRefPubMedGoogle Scholar
- 8.Ogura Y, Roider J, Korobelnik JF, Holz FG, Simader C, Schmidt-Erfurth U, Vitti R, Berliner AJ, Hiemeyer F, Stemper B, Zeitz O, Sandbrink R (2014) Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion. 18-month results of the phase 3 GALILEO study. Am J Ophthalmol 158:1032–1038CrossRefPubMedGoogle Scholar